Lymphoma Classification and Features

Lymphoma, a malignancy of the lymphatic system, represents a critical area of study for any aspiring physician. Its classification into Hodgkin and non-Hodgkin subtypes is not just an academic exercise; it directly dictates prognosis, treatment strategies, and patient management. For the MCAT and your medical education, mastering these distinctions—rooted in pathology, presentation, and molecular genetics—is essential for integrating knowledge across biology, biochemistry, and clinical reasoning.

The Foundational Divide: Hodgkin vs. Non-Hodgkin Lymphoma

The most crucial initial step in understanding lymphoma is grasping the fundamental dichotomy between Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). This classification is based primarily on histopathological findings—what is seen under the microscope. Hodgkin lymphoma is defined by the presence of characteristic malignant cells called Reed-Sternberg cells. In contrast, non-Hodgkin lymphomas encompass a vastly larger and more heterogeneous group of over 60 subtypes that lack these specific cells. NHL is significantly more common, accounting for roughly 90% of all lymphoma cases. From an epidemiological perspective, HL has a bimodal age distribution, peaking in young adulthood (20s-30s) and again later in life, while NHL incidence increases steadily with age.

Core Features of Hodgkin Lymphoma

Hodgkin lymphoma is a model of how a small number of malignant cells can drive a complex disease. The hallmark is the Reed-Sternberg cell, a large, abnormal lymphocyte with a unique appearance. Classically, it is binucleated or has a bilobed nucleus, giving the appearance of "owl's eyes" due to prominent, inclusion-like nucleoli. Crucially, these malignant cells are typically scattered within a background of diverse, non-neoplastic reactive cells like lymphocytes, eosinophils, and fibroblasts.

Clinically, HL most often presents with painless cervical lymphadenopathy (swollen lymph nodes in the neck). A key set of systemic symptoms, known as B symptoms, are of major prognostic importance and include: fever (often Pel-Ebstein, a cyclic fever), drenching night sweats, and unexplained weight loss exceeding 10% of body weight in the last 6 months. The disease also has a predictable pattern of spread, typically moving contiguously from one lymph node group to the next, which influences staging and radiation therapy planning.

Major Subtypes of Non-Hodgkin Lymphoma

NHLs are categorized by their cell of origin (B-cell vs. T-cell), growth pattern, and aggressivity. For the MCAT and pre-med foundation, focusing on several high-yield B-cell lymphomas is paramount.

Follicular Lymphoma is a common, indolent (slow-growing) NHL. It originates from germinal center B-cells and microscopically shows a nodular or "follicular" growth pattern that resembles normal lymphoid follicles. While often responsive to treatment, it is typically not curable in advanced stages and can transform into a more aggressive lymphoma.

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common aggressive NHL. As the name implies, it consists of large B-cells that grow in a diffuse pattern, effacing the normal lymph node architecture. It is a clinically urgent diagnosis but is also potentially curable with intensive chemotherapy, making rapid recognition vital.

Burkitt Lymphoma is a highly aggressive B-cell lymphoma with two main clinical forms: endemic (associated with Epstein-Barr virus in Africa) and sporadic. Its most famous molecular signature is a translocation involving the MYC oncogene, most commonly t(8;14). This translocation places the MYC gene under the control of a powerful immunoglobulin promoter, leading to uncontrolled cell proliferation. Morphologically, it exhibits a "starry sky" pattern due to numerous macrophages engulfing apoptotic tumor cells.

Mantle Cell Lymphoma is an NHL with intermediate aggressivity, derived from naive B-cells in the mantle zone of the lymphoid follicle. A defining genetic feature is the chromosomal translocation t(11;14), which brings the cyclin D1 gene under immunoglobulin gene control, leading to dysregulated cell cycle progression. It often presents with widespread disease, including involvement of the gastrointestinal tract.

Molecular Genetics and Diagnostic Relevance

Understanding the genetic underpinnings is no longer esoteric; it is central to modern diagnosis and therapy. Translocations are cardinal features for specific lymphomas. As noted, t(8;14) with MYC translocation is pathognomonic for Burkitt lymphoma, while t(11;14) leading to cyclin D1 overexpression is the hallmark of mantle cell lymphoma. These are not just test facts; they are detected via techniques like fluorescence in situ hybridization (FISH) and are prime examples of how basic science concepts in genetics and cell cycle regulation translate directly to clinical diagnostics and targeted therapies.

Common Pitfalls

1. Confusing Hodgkin and Non-Hodgkin based on symptoms alone. While HL classically presents with painless cervical nodes, NHL can present similarly. The definitive diagnosis always requires a lymph node biopsy to identify Reed-Sternberg cells (or their absence).
2. Misremembering key genetic translocations. A common error is to associate the MYC translocation with lymphomas other than Burkitt. For recall: Burkitt is "MYC-fast" (aggressive, t(8;14)). Mantle cell has t(11;14) for cyclin D1.
3. Overlooking "B Symptoms." These are not minor complaints. On exams and in practice, the presence of fever, night sweats, or significant weight loss upstages the disease (to Stage B) and influences treatment intensity. They are a critical piece of the clinical history.
4. Equating "indolent" with "harmless." Follicular lymphoma is indolent but still a serious, systemic malignancy requiring monitoring or treatment. It is chronic and often incurable, unlike aggressive lymphomas like DLBCL which can be cured.

Summary

• Lymphomas are fundamentally divided into Hodgkin Lymphoma (HL), characterized by Reed-Sternberg cells, and the more common Non-Hodgkin Lymphoma (NHL), which includes numerous subtypes.
• HL often presents in young adults with painless cervical lymphadenopathy and systemic B symptoms (fever, night sweats, weight loss).
• Key NHL subtypes include indolent Follicular lymphoma, aggressive Diffuse Large B-Cell Lymphoma (DLBCL), highly aggressive Burkitt lymphoma (with pathognomonic t(8;14) MYC translocation), and Mantle cell lymphoma (with t(11;14) causing cyclin D1 overexpression).
• Molecular genetics, especially specific chromosomal translocations, are essential diagnostic and prognostic markers that exemplify the direct link between basic molecular biology and clinical medicine.
• Always base the definitive diagnosis on histopathology (biopsy), and remember that clinical presentation guides the differential but does not provide the final answer.